Prot #X34001/NU 18H02: A Phase 1 Study of R-CHOP Plus SYK Inhibitor TAK-659 for the Front-Line Treatment of High-Risk Diffuse Large B cell Lymphoma (DLBCL)

Project: Research project

Project Details

StatusActive
Effective start/end date2/19/19 → 2/19/24

Funding

  • GMA Research Corporation (Prot #X34001/NU 18H02)
  • Millennium Pharmaceuticals, Inc (Prot #X34001/NU 18H02)